Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice

来自 EBSCO

喜欢 0

阅读量：

113

作者：

S Steffens，Veillard, NR，C Arnaud，G Pelli，F Burger，C Staub，A Zimmer，Frossard, JL，F Mach

展开

摘要：

Atherosclerosis is a chronic inflammatory disease, and is the primary cause of heart disease and stroke in Western countries. Derivatives of cannabinoids such as delta-9-tetrahydrocannabinol (THC) modulate immune functions and therefore have potential for the treatment of inflammatory diseases. We investigated the effects of THC in a murine model of established atherosclerosis. Oral administration of THC (1 mg kg(-1) per day) resulted in significant inhibition of disease progression. This effective dose is lower than the dose usually associated with psychotropic effects of THC. Furthermore, we detected the CB2 receptor (the main cannabinoid receptor expressed on immune cells) in both human and mouse atherosclerotic plaques. Lymphoid cells isolated from THC-treated mice showed diminished proliferation capacity and decreased interferon-gamma secretion. Macrophage chemotaxis, which is a crucial step for the development of atherosclerosis, was also inhibited in vitro by THC. All these effects were completely blocked by a specific CB2 receptor antagonist. Our data demonstrate that oral treatment with a low dose of THC inhibits atherosclerosis progression in the apolipoprotein E knockout mouse model, through pleiotropic immunomodulatory effects on lymphoid and myeloid cells. Thus, THC or cannabinoids with activity at the CB2 receptor may be valuable targets for treating atherosclerosis.

展开

关键词：

E-DEFICIENT MICE LESION FORMATION RECEPTOR-DEFICIENT CB2 RECEPTOR LYMPHOCYTES DELTA-9-TETRAHYDROCANNABINOL INFLAMMATION EXPRESSION CELLS DELTA(9)-TETRAHYDROCANNABINOL